Opus Genetics logo

Opus Genetics (IRD) Q4 2025 Annual Earnings

IRD·Reported May 21, 2026·Before market open

Opus Genetics reported Q4 2025 revenue of $3.9M (-10.2% YoY), beat analyst consensus of $3.1M by $721.0K. Diluted EPS came in at $-0.19 (+85.0% YoY), missed the $-0.16 consensus by $0.03.

Revenue
$3.9Mbeat by $721.0K
Consensus: $3.1M
Diluted EPS
$-0.19missed by $0.03
Consensus: $-0.16
SEC

SEC Filings

Earnings release8-K not filed yet
Annual report10-K · 0001140361-26-009247

Financial Snapshot

Trailing eight quarters through Q4 2025

View all metrics

Q4 2025 Earnings FAQ

Common questions about Opus Genetics's Q4 2025 earnings report.

Opus Genetics (IRD) reported Q4 2025 earnings on May 21, 2026 before market open.

Opus Genetics reported revenue of $3.9M and diluted EPS of $-0.19 for Q4 2025.

Revenue beat the consensus estimate of $3.1M by $721.0K. EPS missed the consensus estimate of $-0.16 by $0.03.

Compared to the same quarter a year prior, revenue declined 10.2% from $4.3M a year earlier and diluted EPS grew 85.0% from $-1.27.

You can read the 10-K periodic report (0001140361-26-009247) directly on SEC EDGAR. The filing index links above go to sec.gov.